Juglone induces GSDME axis pyroptosis in osteosarcoma cells via the JNK/P38 MAPK pathway.

Authors

Jierui Zhao, Xingyu Zhao, Yue Lu, He Wang, Yuhan Zhang, Yi Wang, LiChun Xing, Yumiao Guo, Peng Peng, Wei Zhang, Qibiao Wu

Published in

Scientific reports. Jun 23, 2026. Epub Jun 23, 2026.

Abstract

The MAPK signaling pathway plays a considerable role in cancer inhibition, and pyroptosis is a type of programmed cell death (PCD); thus, it is essential for cellular activity and cancer progression. Juglone can inhibit the viability and motility of cancer cells, but it is unclear whether it can induce pyroptosis in cancer cells, and the corresponding regulatory mechanisms are not well understood. This study explored the in vitro effects of juglone on OS cells, further revealing its ability to induce pyroptosis via the caspase-3/GSDME pathway. Moreover, juglone can regulate the GSDME pathway to induce both pyroptosis and apoptosis through the JNK/p38 pathway. These findings suggest that juglone has potential as a therapeutic agent for osteosarcoma.

PMID:
42337299
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.